The Efficacy and Disadvantages of Endovascular Therapy for Deep-Seated Cerebral Arteriovenous Malformations: A Long-Term Follow-Up Study.

Abstract

Arteriovenous malformations (AVMs) in the basal ganglia, the thalamus, and the insular lobe of the brain are rare and difficult-to-treat diseases that require integrated multimodal management. This study aimed to determine the safety and disadvantages of embolization as an independent therapy for deep-seated AVMs. The authors reviewed 76 patients from a single center with cerebral deep-seated AVMs from 2010 to 2020. Clinical hemorrhage refers to the initial clinical presentation with bleeding, the first occurrence of bleeding, and delayed postoperative hemorrhage refers to subsequent bleeding following the initial hemorrhage. After interventional therapy, 8 patients experienced delayed postoperative hemorrhage during the total follow-up of 94,631 person-years, with an annual postoperative hemorrhage rate of 3.1%. Compared with the overall clinical hemorrhage rate before treatment (15.9%/person-year), 11 patients experienced clinical hemorrhage during 25,238 person-years, indicating a significantly decreased risk of clinical hemorrhage after treatment. A total of 28.9% (22/76) of patients achieved angiographic obliteration. Multivariate analysis showed that pretreatment limb weakness and a high Spetzler-Martin grade predicted poor clinical outcomes (P = 0.043 and 0.005). Fewer feeding arteries predicted AVMs' obliteration (P = 0.048). Endovascular procedure-related complications, mortality, and morbidity were, respectively, reported in 7.9% (6/76), 1.3% (1/76), and 14.8% (8/54) of patients. Endovascular embolization significantly lowered the risk of clinical deterioration and delayed hemorrhage, indicating it to be a safe and effective therapy for deep-seated AVMs. Lesions with a simple angioarchitecture were more likely to be completely obliterated.